RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aldeyra Therapeutics Stock

Aldeyra Therapeutics Revenue 2024

Aldeyra Therapeutics Revenue

29 M USD

Ticker

ALDX

ISIN

US01438T1060

WKN

A111X8

In 2024, Aldeyra Therapeutics's sales reached 29 M USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Aldeyra Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e208.15-
2028e177.89-
2027e116.18-
2026e76.13-
2025e36.35-
2024e29-
2023--
2022--
2021--
2020--
2019--
2018--
2017--
2016--
2015--
2014--
2013--
2012--
2011--

Aldeyra Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aldeyra Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aldeyra Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aldeyra Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aldeyra Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aldeyra Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aldeyra Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aldeyra Therapeutics’s growth potential.

Aldeyra Therapeutics Revenue, EBIT and net profit per share

DateAldeyra Therapeutics RevenueAldeyra Therapeutics EBITAldeyra Therapeutics Net Income
2029e208.15 M undefined0 undefined69.85 M undefined
2028e177.89 M undefined33.39 M undefined86.56 M undefined
2027e116.18 M undefined-3.97 M undefined46.16 M undefined
2026e76.13 M undefined-1.35 M undefined6.29 M undefined
2025e36.35 M undefined-60.52 M undefined-39.54 M undefined
2024e29 M undefined-59.25 M undefined-40.78 M undefined
20230 undefined-42.79 M undefined-37.54 M undefined
20220 undefined-62.68 M undefined-62.02 M undefined
20210 undefined-56.22 M undefined-57.78 M undefined
20200 undefined-34.67 M undefined-37.55 M undefined
20190 undefined-56.5 M undefined-60.83 M undefined
20180 undefined-39.7 M undefined-38.89 M undefined
20170 undefined-22.49 M undefined-22.34 M undefined
20160 undefined-18.7 M undefined-18.7 M undefined
20150 undefined-11.99 M undefined-12.09 M undefined
20140 undefined-7.27 M undefined-9.57 M undefined
20130 undefined-3.68 M undefined1.11 M undefined
20120 undefined-1.12 M undefined-39.13 M undefined
20110 undefined-2.11 M undefined-2.59 M undefined

Aldeyra Therapeutics stock margins

The Aldeyra Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aldeyra Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aldeyra Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aldeyra Therapeutics's sales revenue. A higher gross margin percentage indicates that the Aldeyra Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aldeyra Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aldeyra Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aldeyra Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aldeyra Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aldeyra Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aldeyra Therapeutics Margin History

Aldeyra Therapeutics Gross marginAldeyra Therapeutics Profit marginAldeyra Therapeutics EBIT marginAldeyra Therapeutics Profit margin
2029e0 %0 %33.56 %
2028e0 %18.77 %48.66 %
2027e0 %-3.42 %39.73 %
2026e0 %-1.77 %8.27 %
2025e0 %-166.47 %-108.78 %
2024e0 %-204.32 %-140.65 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %

Aldeyra Therapeutics Aktienanalyse

What does Aldeyra Therapeutics do?

Aldeyra Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for serious eye and immune system diseases. The company was founded in 2004 by Dr. Tod B. Zimmerman and is headquartered in Lexington, Massachusetts. The history of Aldeyra Therapeutics began with the discovery of a new approach to treating inflammatory diseases. The company identified a new class of compounds known as aldehyde binding agents that help reduce the effects of chronic inflammation. In 2013, Aldeyra went public and raised $15 million to advance the development of its products. Aldeyra Therapeutics' business model focuses on building a portfolio of therapies for serious diseases. The company leverages its expertise in drug discovery, development, and commercialization to develop new therapies targeting rare diseases and unmet clinical needs. Aldeyra Therapeutics is divided into two main areas: ophthalmology and immunology. In the ophthalmology field, the company focuses on developing therapies for the treatment of dry eye, pterygium, conjunctivitis, and other eye diseases. In the immunology field, the company aims to develop therapies for immune-related diseases such as asthma, chronic obstructive pulmonary disease (COPD), autoimmune diseases, and others. One key product of Aldeyra Therapeutics is the drug reproxalap, which was developed to halt the progression of dry eye disease. Reproxalap is an aldehyde binding agent designed to help reduce inflammation, pain, and redness in patients with dry eye. The company plans to conduct further clinical trials for reproxalap to facilitate its submission for approval to the US Food and Drug Administration (FDA). Another product in the immunology field is ADX-1612, an aldehyde binding agent targeting the treatment of asthma. The clinical trials are still in the early phases, but preliminary data provide hope that ADX-1612 could become an important component of asthma therapy in the future. Aldeyra Therapeutics does not work alone. The company has partnerships with other biotech or pharmaceutical companies, such as in the development of therapeutics for rare immunological and eye diseases or the development of diagnostic tests for a specific eye disease. The company hopes that its research and development efforts will ultimately help improve the lives of people with serious diseases. Although there is a risk of setbacks in the development of new therapies, it is hoped that Aldeyra Therapeutics will find new ways in the future to address the unmet needs of patients in need. Aldeyra Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Aldeyra Therapeutics's Sales Figures

The sales figures of Aldeyra Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Aldeyra Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Aldeyra Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Aldeyra Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Aldeyra Therapeutics stock

How much revenue did Aldeyra Therapeutics generate this year?

Aldeyra Therapeutics has achieved a revenue of 29 M USD this year.

How much was the turnover of the company Aldeyra Therapeutics compared to the previous year?

The revenue of Aldeyra Therapeutics has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Aldeyra Therapeutics?

The revenue of Aldeyra Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Aldeyra Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Aldeyra Therapeutics so important for investors?

The revenue of Aldeyra Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Aldeyra Therapeutics pay?

Over the past 12 months, Aldeyra Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aldeyra Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aldeyra Therapeutics?

The current dividend yield of Aldeyra Therapeutics is .

When does Aldeyra Therapeutics pay dividends?

Aldeyra Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aldeyra Therapeutics?

Aldeyra Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aldeyra Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aldeyra Therapeutics located?

Aldeyra Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aldeyra Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aldeyra Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Aldeyra Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Aldeyra Therapeutics in the year 2023?

In the year 2023, Aldeyra Therapeutics distributed 0 USD as dividends.

In which currency does Aldeyra Therapeutics pay out the dividend?

The dividends of Aldeyra Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aldeyra Therapeutics

Our stock analysis for Aldeyra Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aldeyra Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.